| 头孢哌酮与莫西沙星治疗肺部感染的疗效对比 |
| |
| 引用本文： | 杨炜,陈力. 头孢哌酮与莫西沙星治疗肺部感染的疗效对比[J]. 中国医院用药评价与分析, 2009, 0(7): 540-541 |
| |
| 作者姓名： | 杨炜 陈力 |
| |
| 作者单位： | [1]成都市第六人民医院呼吸内科,成都市610051 [2]成都铁路中心医院老年科,成都市610081 |
| |
| 摘 要： | 目的：比较头孢哌酮与莫西沙星治疗肺部感染的疗效及其安全性。方法：共选入肺部感染住院患者120例,随机分为两组,其中应用头孢哌酮治疗60例、莫西沙星治疗60例。结果：头孢哌酮组有效率86.7%,莫西沙星组有效率93.3%;对致病菌株的清除率分别为83%和90.8%;不良反应发生率分别为5%与3.3%,两者临床疗效无明显差异（P〉0.05）。结论：头孢哌酮与莫西沙星都是安全有效治疗肺部感染的药物。
|
| 关 键 词： | 头孢哌酮 莫西沙星 肺部感染 临床疗效 安全性 |
Cefoperazone vs. Moxifloxacin in the Treatment of Pulmonary Infection |
| |
| YANG Wei,CHEN Li. Cefoperazone vs. Moxifloxacin in the Treatment of Pulmonary Infection[J]. Evaluation and Analysis of Drug-Use in Hospital of China, 2009, 0(7): 540-541 |
| |
| Authors: | YANG Wei CHEN Li |
| |
| Affiliation: | 1. Dept. of Respiratory Medicine, Chengdu Sixth People＇s Hospital, Chengdu 610015, China; 2.Dept. of Geriatrics, Chengdu Railroad Central Hospital, Chengdu 610082, China) |
| |
| Abstract: | OBJECTIVE：To evaluate the therapeutic efficacy and adverse reactions of cefoperazone vs.moxifloxacin for pulmonary infection.METHODS：120 inpatients with pulmonary infection were randomly assigned to receive cefoperazone（n=60） or moxifloxacin（n=60）.RESULTS：There were no significant differences between the cefoperazone group and the moxifloxacin group in clinical efficacy（P〉0.05）（effective rate：86.7% vs.93.3%;bacterial clearance rate：83% vs.90.8%;incidence of adverse reactions：5% vs.3.3%） CONCLUSION：Both cefoperazone and moxifloxacin are safe and effective for patients with pulmonary infection. |
| |
| Keywords: | Cefoperazone Moxifloxacin Pulmonary infection Clinical efficacy Safety |
| 本文献已被 维普 等数据库收录！ |
|
